Logo image of 1VRTX.MI

VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Fundamental Analysis

BIT:1VRTX - US92532F1003 - Common Stock

336.75 EUR
-47.85 (-12.44%)
Last: 8/19/2025, 7:00:00 PM
Fundamental Rating

6

1VRTX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. 1VRTX has an excellent financial health rating, but there are some minor concerns on its profitability. 1VRTX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year 1VRTX has reported negative net income.
In the past year 1VRTX has reported a negative cash flow from operations.
1VRTX had positive earnings in 4 of the past 5 years.
Of the past 5 years 1VRTX 4 years had a positive operating cash flow.
1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

With a decent Return On Assets value of -4.32%, 1VRTX is doing good in the industry, outperforming 64.38% of the companies in the same industry.
The Return On Equity of 1VRTX (-5.99%) is better than 69.86% of its industry peers.
The Return On Invested Capital of 1VRTX (16.53%) is better than 90.41% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1VRTX is above the industry average of 13.68%.
Industry RankSector Rank
ROA -4.32%
ROE -5.99%
ROIC 16.53%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.48%
ROIC(5y)19.13%
1VRTX.MI Yearly ROA, ROE, ROIC1VRTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

With an excellent Operating Margin value of 37.91%, 1VRTX belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
In the last couple of years the Operating Margin of 1VRTX has grown nicely.
1VRTX has a Gross Margin of 86.03%. This is in the better half of the industry: 1VRTX outperforms 75.34% of its industry peers.
In the last couple of years the Gross Margin of 1VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 37.91%
PM (TTM) N/A
GM 86.03%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
1VRTX.MI Yearly Profit, Operating, Gross Margins1VRTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

1VRTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 1VRTX has less shares outstanding
1VRTX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for 1VRTX has been reduced compared to a year ago.
1VRTX.MI Yearly Shares Outstanding1VRTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
1VRTX.MI Yearly Total Debt VS Total Assets1VRTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

1VRTX has an Altman-Z score of 11.47. This indicates that 1VRTX is financially healthy and has little risk of bankruptcy at the moment.
1VRTX has a better Altman-Z score (11.47) than 90.41% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that 1VRTX is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.01, 1VRTX belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 11.47
ROIC/WACC1.7
WACC9.73%
1VRTX.MI Yearly LT Debt VS Equity VS FCF1VRTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 2.65 indicates that 1VRTX has no problem at all paying its short term obligations.
1VRTX has a Current ratio of 2.65. This is in the better half of the industry: 1VRTX outperforms 63.01% of its industry peers.
A Quick Ratio of 2.29 indicates that 1VRTX has no problem at all paying its short term obligations.
1VRTX's Quick ratio of 2.29 is fine compared to the rest of the industry. 1VRTX outperforms 61.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.65
Quick Ratio 2.29
1VRTX.MI Yearly Current Assets VS Current Liabilites1VRTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

6

3. Growth

3.1 Past

1VRTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.42%.
1VRTX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
The Revenue has grown by 8.98% in the past year. This is quite good.
Measured over the past years, 1VRTX shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%

3.2 Future

Based on estimates for the next years, 1VRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 152.83% on average per year.
The Revenue is expected to grow by 10.19% on average over the next years. This is quite good.
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1VRTX.MI Yearly Revenue VS Estimates1VRTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
1VRTX.MI Yearly EPS VS Estimates1VRTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1VRTX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 18.50 indicates a rather expensive valuation of 1VRTX.
82.19% of the companies in the same industry are more expensive than 1VRTX, based on the Price/Forward Earnings ratio.
1VRTX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 18.5
1VRTX.MI Price Earnings VS Forward Price Earnings1VRTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1VRTX is valued a bit cheaper than 75.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.01
1VRTX.MI Per share data1VRTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

1VRTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of 1VRTX may justify a higher PE ratio.
A more expensive valuation may be justified as 1VRTX's earnings are expected to grow with 332.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y753.07%
EPS Next 3Y332.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1VRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERTEX PHARMACEUTICALS INC

BIT:1VRTX (8/19/2025, 7:00:00 PM)

336.75

-47.85 (-12.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap86.48B
Analysts75
Price Target438.94 (30.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.13%
Min EPS beat(2)-7.2%
Max EPS beat(2)-3.07%
EPS beat(4)1
Avg EPS beat(4)-133.54%
Min EPS beat(4)-527.57%
Max EPS beat(4)3.69%
EPS beat(8)4
Avg EPS beat(8)-65%
EPS beat(12)7
Avg EPS beat(12)-42.16%
EPS beat(16)10
Avg EPS beat(16)-29.51%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)2.68%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.75%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-6.62%
PT rev (3m)-6.62%
EPS NQ rev (1m)-1.55%
EPS NQ rev (3m)-1.55%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-0.75%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.5
P/S 9.03
P/FCF N/A
P/OCF N/A
P/B 6.08
P/tB 6.7
EV/EBITDA 21.01
EPS(TTM)-0.35
EYN/A
EPS(NY)18.2
Fwd EY5.41%
FCF(TTM)-4.23
FCFYN/A
OCF(TTM)-3.29
OCFYN/A
SpS37.28
BVpS55.41
TBVpS50.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.32%
ROE -5.99%
ROCE 22.04%
ROIC 16.53%
ROICexc 24.47%
ROICexgc 27.77%
OM 37.91%
PM (TTM) N/A
GM 86.03%
FCFM N/A
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.48%
ROIC(5y)19.13%
ROICexc(3y)48.36%
ROICexc(5y)53.43%
ROICexgc(3y)69.79%
ROICexgc(5y)83.16%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 137.41%
Cap/Sales 2.5%
Interest Coverage 181.38
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.65
Quick Ratio 2.29
Altman-Z 11.47
F-Score4
WACC9.73%
ROIC/WACC1.7
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%
EBIT growth 1Y-1.84%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year827.23%
EBIT Next 3Y131%
EBIT Next 5Y70.83%
FCF growth 1Y-132.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.06%
OCF growth 3YN/A
OCF growth 5YN/A